U.S. Biotech Stock News

Mineralys Therapeutics recently reported that the FDA accepted its New Drug Application for lorundrostat for adults with hypertension, setting a PDUFA target action date of December 22, 2026, based on multiple trials showing blood pressure reductions and a favorable safety profile. Although the Phase 2 Explore-OSA study did not improve sleep apnea severity, its blood pressure benefit in a difficult-to-treat, obese hypertensive population highlights lorundrostat’s potential relevance across...

If you are wondering whether Open Text's share price still reflects its underlying business, you are not alone. This article looks at what the numbers say about value rather than headlines. At a last close of US$23.99, the stock has seen returns of a 4.3% decline over 7 days, a 5.4% decline over 30 days, a 24.4% decline year to date and a 1.6% decline over the past year, with a 25.5% decline over 3 years and a 43.3% decline over 5 years. Recent trading has been shaped by ongoing investor...

Amcor (NYSE:AMCR) is back in focus after its North American unit issued US$1.5b in senior unsecured guaranteed notes to refinance near term debt, following a recent 4.38% intraday share price drop. See our latest analysis for Amcor. That refinancing move comes after a choppy stretch, with a 7 day share price return of 7.37% and a 30 day share price return of 12.21%. However, the 1 year total shareholder return of 9.32% signals weak longer term momentum. If this kind of debt focused news has...

Ally Financial (ALLY) has rolled out an AI pilot for collections calls, drawing fresh attention to how this Detroit based digital bank is using automation to reshape operations in a tougher auto finance market. See our latest analysis for Ally Financial. Despite the AI rollout and recent conference commentary, Ally Financial’s 1 day share price return of a 1.42% decline and 7 day share price return of an 8.81% decline show pressure building in the short term, while its 1 year total...

If you are wondering whether Atmos Energy's share price still reflects fair value or if the market is getting ahead of itself, you are not alone. The stock last closed at US$184.30, with returns of 7.5% over 30 days, 8.8% year to date, 28.0% over 1 year, 74.4% over 3 years and 125.9% over 5 years. This recent performance is likely influencing how investors think about risk and upside. Recent evergreen coverage has focused on Atmos Energy's role as a regulated gas utility and how investors...

Babcock & Wilcox Enterprises (BW) just paired a profitable fourth quarter with a newly amended credit agreement, combining improved earnings with added borrowing capacity and extended debt maturities that could matter for investors watching its turnaround story. See our latest analysis for Babcock & Wilcox Enterprises. The turnaround signs appear to have caught the market’s attention, with a 1-day share price return of 5.13% and a 90-day share price return of 137.30% feeding into a very large...

Duolingo (DUOL) is back in focus after management told investors it will prioritize user growth, upgrade its free tier and aim to double daily active users by 2028, even if near term earnings take a hit. See our latest analysis for Duolingo. The recent focus on user growth comes after a sharp reset in sentiment, with Duolingo’s 1 day share price return of 3.81% and 7 day return of 2.75% sitting against a 30 day share price return decline of 16.90% and a year to date share price return decline...

Carter's, Inc. recently reported past fourth-quarter and full-year 2025 results showing higher quarterly sales and earnings year-on-year, issued 2026 net sales growth guidance, affirmed a US$0.25 quarterly dividend, and confirmed completion of a US$97.57 million buyback program initiated in 2022. Despite no share repurchases in fiscal 2025 and a sharp year-on-year drop in full-year net income to US$91.8 million, management’s guidance for net sales growth and continued dividend payments...

If you are wondering whether ResMed at around US$240.15 is offering good value today, you are not alone. The stock sits at a point where valuation really matters for the next move. Over the short term the share price has been volatile, with a 7.3% decline over the last week and a 13.0% decline over the last month, even though the 1 year return sits at 10.0% and the 5 year return at 30.9%. Recent headlines around ResMed have focused on its position in sleep and respiratory care devices and...

Serve Robotics (SERV) is back in focus after raising its 2026 revenue outlook to about US$26 million, pairing that guidance with a new White Castle delivery partnership and fresh fourth quarter and full year 2025 results. See our latest analysis for Serve Robotics. The raised 2026 revenue outlook and White Castle partnership arrive after a mixed price picture, with a 1 day share price return of 10.13% and a year to date share price decline of 9.97%, while the 1 year total shareholder return...

Generac Holdings (NYSE:GNRC) received multiple GOOD DESIGN Awards for products in home standby, portable generators, and energy storage systems. The recognition covers several product lines that focus on design, usability, and sustainability. The awards highlight Generac’s efforts to differentiate within the broader energy technology and backup power market. For you as an investor, this recognition ties directly to how Generac positions itself across backup power and energy management. The...

Trump Media & Technology Group (NasdaqGM:DJT) has outlined a pivot toward Bitcoin treasury management as a primary business activity. The company plans to expand its financial assets, introduce bitcoin linked options, and pursue new ventures tied to ETFs and prediction markets. Management has also flagged initiatives in AI powered search and a potential merger related to fusion energy as part of a broader shift beyond the Truth Social platform. For investors following Trump Media &...

Recently, Western Midstream Partners restructured its long-term agreement with Occidental into a fixed-fee contract with minimum volume commitments through 2035, with Occidental also returning shares worth about US$610 million, while expanding agreements with ConocoPhillips and growing its produced water operations. This combination of long-duration fee-based contracts, asset-light water infrastructure expansion, and a significant equity giveback from Occidental could reshape Western...

Why Visteon Stock Is Drawing Fresh Attention Visteon (VC) is back on many investors’ radars after a period of mixed share performance, with the stock showing a 9.4% total return over the past year but weaker recent momentum. At a last close of US$90.67, Visteon sits against a backdrop of annual revenue of US$3.8b and net income of US$201 million, giving investors concrete numbers to weigh against recent volatility. See our latest analysis for Visteon. Recent trading has been softer, with a 30...

If you are wondering whether L3Harris Technologies is priced fairly after its recent run, this article will help you make sense of where the stock sits on the value spectrum. The share price recently closed at US$364.26, with returns of 3.9% over 30 days and 19.6% year to date, while the 1 year return stands at 77.3% and the 5 year figure at 109.6%. Recent news around L3Harris has focused on its role in defense and aerospace, with investors watching how contract activity and sector sentiment...

On March 9, 2026, Archer-Daniels-Midland expanded its Board to 13 members by appointing former LyondellBasell CFO Michael McMurray, who will serve on the Audit and Sustainability and Technology committees. By adding a director with extensive financial and industrial experience, ADM is signaling a reinforced focus on governance, risk oversight, and long-term sustainability priorities. We’ll now examine how McMurray’s appointment to ADM’s Board could influence the company’s investment...

Structure Therapeutics (GPCR) reported fourth quarter net income of US$33 million, compared with a net loss of US$36.48 million a year earlier, marking a clear shift in its recent financial results. See our latest analysis for Structure Therapeutics. Despite the shift to quarterly net income, Structure Therapeutics’ recent share price return has softened, with a 30 day share price return of 26.26% and a year to date share price return of 14.56%. By contrast, the 1 year total shareholder...

Why Madrigal Pharmaceuticals Is On Investors’ Radar Madrigal Pharmaceuticals (MDGL) has attracted fresh attention after recent market moves, with the share price near US$431.53 and returns showing mixed results over the past year and past 3 months. For investors tracking performance, the stock shows a 1 day return of about a 0.3% decline and a 7 day return of roughly a 0.8% decline, while the past month and past 3 months reflect deeper pullbacks. See our latest analysis for Madrigal...

Chevron has relocated its headquarters from California to Houston, citing the regulatory and litigation environment in California. The company is pursuing new oil extraction agreements in Venezuela following recent political changes backed by the US. Chevron's Middle East operations are affected as oil flows through the Strait of Hormuz fall to about 3% of normal levels and Gulf production is disrupted by conflict. For investors watching NYSE:CVX, this cluster of developments goes beyond...

If you are wondering whether Chubb's current share price reflects its true worth, you are not alone. Many investors are asking if the recent price level still offers value. Chubb shares last closed at US$322.76, with returns of 4.1% year to date and 15.2% over the past year, while the stock shows a 3.4% decline over 7 days and a 1.0% decline over 30 days that may have caught your eye. Recent headlines around Chubb have focused on its position in the insurance space and how investors are...

Wondering if Exelon at around US$48.84 is giving you fair value right now, or if the market is missing something important about this utility giant. The stock has been relatively steady over the past week with a 0.8% decline, while its 30 day return of 11.1% and 1 year return of 18.7% may catch the eye of investors who are thinking about growth potential or shifting risk perceptions. Those moves sit against a wider backdrop of ongoing interest in regulated utilities. In this area, investors...

In early March 2026, Hewlett Packard Enterprise reported past first-quarter results showing higher sales of US$8,425 million, raised its full-year 2026 earnings guidance, continued an extensive multi-year share buyback now totaling about US$12.86 billion, and affirmed a regular dividend of US$0.1425 per share. A key insight is that networking has become a central earnings engine, helping drive record per-share profits and stronger guidance, while the company simultaneously returns large...

If you are wondering whether Ralph Lauren's share price still offers value after a strong run, this article will walk through what the current market price might be implying about the business. The stock last closed at US$338.95. While the share price shows a 5.8% decline over 7 days and a 2.6% decline over 30 days, it also shows a 6.5% decline year to date, a 52.4% gain over 1 year, and more than 3x over 3 years. Recent coverage around Ralph Lauren has focused on its brand strength, product...

Perimeter Solutions, Inc. reported past fourth-quarter 2025 sales of US$102.75 million, up from US$86.23 million a year earlier, but swung to a net loss of US$140.23 million and a basic loss per share of US$0.94 from prior-year earnings. For 2025 as a whole, the company increased sales to US$652.86 million while recording a much larger net loss of US$206.37 million, against the backdrop of its role as the sole aerial fire-retardant supplier under a new five-year U.S. Department of...